ATE326956T1 - Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität - Google Patents

Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität

Info

Publication number
ATE326956T1
ATE326956T1 AT98962011T AT98962011T ATE326956T1 AT E326956 T1 ATE326956 T1 AT E326956T1 AT 98962011 T AT98962011 T AT 98962011T AT 98962011 T AT98962011 T AT 98962011T AT E326956 T1 ATE326956 T1 AT E326956T1
Authority
AT
Austria
Prior art keywords
compounds
aminothiole
kidney diseases
drug toxicity
treat nerve
Prior art date
Application number
AT98962011T
Other languages
English (en)
Inventor
Martin Stogniew
David S Alberts
Edward H Kaplan
Original Assignee
Medimmune Oncology Inc
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25533362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE326956(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Oncology Inc, Univ Arizona filed Critical Medimmune Oncology Inc
Application granted granted Critical
Publication of ATE326956T1 publication Critical patent/ATE326956T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT98962011T 1997-12-09 1998-12-09 Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität ATE326956T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/987,550 US5994409A (en) 1997-12-09 1997-12-09 Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds

Publications (1)

Publication Number Publication Date
ATE326956T1 true ATE326956T1 (de) 2006-06-15

Family

ID=25533362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962011T ATE326956T1 (de) 1997-12-09 1998-12-09 Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität

Country Status (13)

Country Link
US (7) US5994409A (de)
EP (2) EP1039887B1 (de)
JP (2) JP2001525359A (de)
CN (1) CN1161113C (de)
AT (1) ATE326956T1 (de)
AU (1) AU739068B2 (de)
BR (1) BR9813524A (de)
CA (1) CA2313089C (de)
DE (1) DE69834658T2 (de)
DK (1) DK1039887T3 (de)
ES (1) ES2260857T3 (de)
PT (1) PT1039887E (de)
WO (1) WO1999029312A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
WO2001070220A1 (en) * 2000-03-22 2001-09-27 Neopharm, Inc. A method of administering liposomal encapsulated taxane
DE60118172T2 (de) * 2000-04-26 2007-03-08 Oregon Health Sciences University, Portland Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
JP4995396B2 (ja) * 2000-06-14 2012-08-08 アメリカ合衆国 植物性エストロゲンのイソフラボン組成物、それらの製剤及び放射線傷害に対する防護および処置用のその使用
AU2001287021A1 (en) * 2000-08-30 2002-03-13 Oregon Health And Science University Chemoprotectant for gastric toxicity
DE60117043T2 (de) * 2000-11-22 2006-07-13 Rxkinetix, Inc., Louisville Behandlung von mukositis
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
WO2003026570A2 (en) * 2001-09-24 2003-04-03 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
CN100391941C (zh) * 2001-12-07 2008-06-04 海门慧聚药业有限公司 一种胺基硫醇及其硫代衍生物
EP2266590A3 (de) 2002-02-22 2011-04-20 Shire LLC Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
US7981928B2 (en) * 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
US20040146585A1 (en) * 2002-10-31 2004-07-29 Oregon Health & Science University Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
EA200501252A1 (ru) * 2003-02-03 2006-02-24 Неофарм, Инк. Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
WO2004080429A2 (en) * 2003-03-13 2004-09-23 Oregon Health & Science University Use of thiol-based compositions in ameliorating mucosal injury
US8580321B2 (en) * 2003-12-02 2013-11-12 The Cleveland Clinic Foundation Method for reducing the effects of chemotherapy using flagellin related polypeptides
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20060121016A1 (en) * 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
US20070082858A1 (en) * 2004-12-21 2007-04-12 Oregon Health & Science University Methods and compositions for the prevention of toxic side effects of aminoglycoside medications
EP1838340B1 (de) 2004-12-22 2018-04-04 Cleveland Clinic Foundation Mit flagellin verwandte polypeptide und ihre verwendungen
ES2473665T3 (es) * 2005-11-28 2014-07-07 Verrow Pharmaceuticals, Inc. Composiciones útiles para reducir la nefrotoxicidad y los métodos de uso de las mismas
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US9585849B2 (en) * 2006-04-17 2017-03-07 The Burlington Hc Research Group, Inc. Broad spectrum antiviral and methods of use
US20090239817A1 (en) * 2006-04-17 2009-09-24 Goverment Of The United States Of America, As Represented By The Secretary, Dept Of Health Organic thiophosphate antiretroviral agents
US8138227B2 (en) * 2006-07-06 2012-03-20 Trustees Of Dartmouth College Method for inhibiting or reversing non-enzymatic glycation
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
WO2008060441A2 (en) * 2006-11-09 2008-05-22 Scidose Llc Stable amifostine liquid concentrate
EP2141995B1 (de) 2007-03-27 2014-11-05 Perscitus Biosciences, LLC Zusammensetzungen und ihre verwendungen zum schutz von zellen gegen toxische wirkungen
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
AU2008331109B2 (en) * 2007-11-28 2014-04-10 Christian-Albrechts-Universitat Zu Kiel Methods for the treatment of radiation or chemotherapy-induced tissue damage
ES2476602T3 (es) * 2008-03-14 2014-07-15 Bionumerik Pharmaceuticals, Inc. Composiciones y métodos quimioprotectores
PT2320948E (pt) 2008-08-01 2013-06-17 Cleveland Clinic Foundation Métodos para o tratamento de lesões por reperfusão
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
US9376473B2 (en) 2011-01-10 2016-06-28 Cleveland Biolabs, Inc. Use of Toll-Like Receptor agonist for treating cancer
US20140050728A1 (en) * 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US20160143926A1 (en) * 2013-06-18 2016-05-26 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
EP3174893B1 (de) 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellinzusammensetzungen und verwendungen
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
CN107753490B (zh) * 2017-11-19 2018-07-27 宋在明 一种治疗肿瘤放疗所致口腔黏膜炎的透皮给药制剂
JP2022537518A (ja) * 2019-06-13 2022-08-26 シャンハイ ケチョウ ファーマ，インコーポレイテッド 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
CN114712350B (zh) * 2021-12-28 2024-04-12 中国医学科学院放射医学研究所 Dttz在制备预防、治疗化疗损伤药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
US4742050B1 (en) 1982-08-17 1994-06-28 Alpha Therapeutic Corp Sensitization of hypoxic tumor cells and control of growth thereof
US4656034A (en) 1985-05-20 1987-04-07 Survival Technology, Inc. Absorption enhancing agents
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
WO1988007942A1 (en) 1987-04-15 1988-10-20 Freezone Pty Ltd A tyre bead breaker
US5091180A (en) 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
DE3888541T2 (de) * 1987-12-22 1994-06-23 U S Bioscience Blue Bell Verbesserung der toxizitätskurven in der chemotherapie.
US5112954A (en) 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
AU638251B2 (en) * 1989-05-24 1993-06-24 U.S. Bioscience, Inc. Method for protection from azt side effects and toxicity
US5167947A (en) 1989-10-26 1992-12-01 Southwest Research Institute Enhancement of absorption of radioprotective drugs
US5217964A (en) 1991-01-23 1993-06-08 Merrell Dow Pharmaceuticals Inc. Polyamine thiols as radioprotective agents
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
US5869338A (en) * 1992-03-13 1999-02-09 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5567686A (en) * 1992-03-13 1996-10-22 Arch Development Corporation Method for protection against genotoxic mutagenesis
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5618823A (en) 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en) * 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
DE4234257A1 (de) * 1992-10-10 1994-04-14 Roehm Gmbh Verfahren zur Herstellung von Thiol(meth)acrylaten
KR100311851B1 (ko) 1993-02-23 2002-04-24 슈테펜엘.네스비트 방사선보호제로서의폴리아민유도체
US5824664A (en) * 1993-03-26 1998-10-20 U.S. Bioscience, Inc. Suppression of HIV expression by organic thiophosphate
CA2124021A1 (en) 1993-05-21 1994-11-22 John Samonides Sr. Adhesive for labels and the like
DE69411271T2 (de) 1993-05-26 1998-11-05 Merrell Pharma Inc N-alkylthiopolyaminderivate als radioprotektive mittel
CA2099070A1 (en) 1993-06-23 1994-12-24 Nelson Mak Process and apparatus for deinking wastepaper with molten fatty acid
US5467947A (en) * 1994-04-08 1995-11-21 Metra Electronics Corporation Mounting kit for mounting one of several types of audio equipment in an automotive dashboard
US5846958A (en) * 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
GB9504995D0 (en) * 1995-03-11 1995-04-26 Zeneca Ltd Compositions
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US5974409A (en) * 1995-08-23 1999-10-26 Microsoft Corporation System and method for locating information in an on-line network
JPH11514990A (ja) * 1995-09-25 1999-12-21 チャチョウア，サミー ２−メルカプトエタノールアミン（２−ｍｅａ）と類縁アミノチオール化合物および３，５−ジイソプロピルサリチル酸銅（▲ｉｉ▼）と類縁化合物の、各種疾患を予防および治療するための使用
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US6110891A (en) 1996-06-21 2000-08-29 Alizyme Therapeutics Ltd. Lectin compositions and uses thereof
US5866591A (en) 1996-09-11 1999-02-02 Glaxo Wellcome Inc. Stable formulations of remifentanil
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5919934A (en) 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy
FR2761606B1 (fr) 1997-04-08 1999-05-14 Cird Galderma Utilisation de derives aminothiolesters dans le domaine pharmaceutique
US6284259B1 (en) * 1997-11-12 2001-09-04 The Procter & Gamble Company Antimicrobial wipes which provide improved residual benefit versus Gram positive bacteria
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
AU2090099A (en) 1997-12-16 1999-07-05 William Darwin Garner Reduction of uv induced skin cancer by topical amines
JPH11240252A (ja) 1997-12-22 1999-09-07 Tdk Corp 光記録媒体
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
US6407278B2 (en) 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6054622A (en) 1998-12-18 2000-04-25 Alliedsignal Inc Aromatic hydroxythiol synthesis using diazonium salts
US6075053A (en) 1999-02-09 2000-06-13 Bionumerik Pharmaceuticals, Inc. Method of reducing or reversing neuropathy
US6489312B1 (en) 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates

Also Published As

Publication number Publication date
JP2001525359A (ja) 2001-12-11
US20060270636A1 (en) 2006-11-30
CA2313089C (en) 2010-10-12
EP1039887B1 (de) 2006-05-24
CA2313089A1 (en) 1999-06-17
US20110166108A1 (en) 2011-07-07
EP1537861A3 (de) 2005-06-15
US20130090312A1 (en) 2013-04-11
US20020132795A1 (en) 2002-09-19
US7105575B2 (en) 2006-09-12
DK1039887T3 (da) 2006-09-11
EP1039887A4 (de) 2003-01-15
JP2006188532A (ja) 2006-07-20
US6586476B1 (en) 2003-07-01
WO1999029312A1 (en) 1999-06-17
AU739068B2 (en) 2001-10-04
ES2260857T3 (es) 2006-11-01
CN1283994A (zh) 2001-02-14
US20060040903A1 (en) 2006-02-23
PT1039887E (pt) 2006-10-31
EP1039887A1 (de) 2000-10-04
DE69834658D1 (de) 2006-06-29
EP1537861A2 (de) 2005-06-08
CN1161113C (zh) 2004-08-11
AU1718499A (en) 1999-06-28
US5994409A (en) 1999-11-30
BR9813524A (pt) 2002-02-19
DE69834658T2 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
ATE326956T1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2&#39;- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE156359T1 (de) Phosphatdiester zur behandlung von proliferativen erkrankungen der epidermis
ATE222109T1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
ATE252387T1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
DE69924979D1 (de) Behandlung von chronischen schmerzen
ATE120447T1 (de) Polyamin-derivate als antineoplastische mittel.
DE69905489T2 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE69528068T2 (de) Conagenine zur prävention und behandlung von diarrhöe
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1039887

Country of ref document: EP